** Contract research firm Charles River Laboratories' CRL.N shares fall 11.1% to $169.01 premarket
** Company forecasts 2025 revenue will decline organically in a similar range as estimated in 2024
** Charles River in November forecast full-year 2024 revenue to decrease 2% to 3%, versus previous expectations of it falling 2.5% to 4.5%
** Company says lower commercial contract drug manufacturing revenue is expected to "reduce consolidated revenue growth by approximately 1% in 2025"
** Charles River says a cell therapy client notified CRL that it would terminate its commercial agreement with the company "to utilize another long-time CDMO partner"
** Company adds that cell and gene therapy client demand "is not as robust as at the time of acquisition, but attractive, long-term growth opportunities exist for its CDMO business"
** Stock fell 21.9% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.